Candel Therapeutics Inc. has appointed Charles Schoch as Chief Financial Officer, transitioning from his role as interim CFO, effective immediately. Schoch has been with Candel since November 2021 and has held various financial positions, most recently as VP of Finance and Corporate Controller. As interim CFO, he led the company through significant financial milestones, including a capital raise of approximately $86 million.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.